发现了第一类具有高度选择性的TRPV1抗剂,具有双重止痛和低血糖效应
Chunxia Liu1, Wenxin Wang2, Shiyu Zhao1
1Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, PR China; Henan Key Laboratory of Precision Clinical Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, PR China.
Bioorganic & medicinal chemistry
|May 22, 2024
概括
研究人员开发了一种新型TRPV1抗剂CX-3,用于治疗糖尿病神经病变的疼痛和高血糖. 作为安全有效的治疗候选药物,CX-3显示出有前途,而不会导致高温症.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病神经病痛在镇痛和血糖控制方面存在重大未满足的临床需求.
- 暂时受体潜在类型-1 (TRPV1) 通道是经过验证的疼痛标,但对手因高热副作用而面临挑战.
研究的目的:
- 设计和识别具有治疗糖尿病神经病痛治疗潜力的新型TRPV1抗剂.
- 在临床前模型中评估化合物CX-3的疗效和安全性.
主要方法:
- 基于结构的药物设计 (SBDD) 用于合成两系列基于黄类的TRPV1抗剂.
- 化合物CX-3被评估为体外TRPV1抗活性,体内在甲素诱导的炎症性疼痛模型中的 analgesic 作用,以及降糖作用.
- 对其他离子通道的选择性进行了评估.
主要成果:
- 化合物CX-3在体外表现出强烈的TRPV1抗活性,与经典抗剂BCTC.BCTC相当.
- 与BCTC相比,CX-3在体内表现出优越的止痛作用,重要的是没有诱导高温症.
- 此外,CX-3还显示出显著的降血糖效应和对TRPV1的高选择性,而不是其他离子通道.
结论:
- CX-3是一种新型,高度选择性的TRPV1抗剂,具有有前途的止痛和降糖特性.
- 这种一流的化合物代表了解决糖尿病神经病痛中疼痛和高血糖症的双重挑战的潜在治疗候选者.
相关概念视频
Glucagon-like Receptor Agonists
318
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318
Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Oral Hypoglycemic Agents: Glinides
153
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
153
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
173
Analgesia and Pain Management
582
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
582


